Home › Cervical Cancer › NCT04743674
Blood and Urine HPVDNA as Minimally Invasive Biomarkers for Cervical Cancer Detection and Surveillance Following Treatment
Plasma Circulating Tumor HPVDNA and Transrenal HPVDNA as Minimally Invasive Biomarkers for Cervical Cancer Detection and Surveillance Following Definitive Treatment
Who can join
Ages 18 and older · Women
Full eligibility criteria
Inclusion Criteria: * 18 years of age or older on day of signing informed consent * New diagnosis of cervical cancer * Subject is willing and able to comply with study procedures based on the judgement of the investigator or protocol designee Exclusion Criteria: * Women who are pregnant
About the study
The purpose of this study is to determine if ctHPVDNA (circulating tumor HPV DNA) can be used as a non-invasive biomarker for identification and treatment monitoring of cervical cancer by characterizing correlation between plasma ctHPVDNA, urine transrenal HPVDNA (TrHPVDNA) levels and presence of cervical cancer at diagnosis and following definitive intent management.
Sponsor: UNC Lineberger Comprehensive Cancer Center · Participants: 30 · Started: May 3, 2024
Contact the study team
- Melissa E Knutsen · Phone: 919-445-4869
Official record on ClinicalTrials.gov — NCT04743674
Locations in the U.S.
| North Carolina | Melissa Knutsen, Chapel Hill |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.